Search

Your search keyword '"Overbeek, Kasper A."' showing total 131 results
Start Over Author "Overbeek, Kasper A."
131 results on '"Overbeek, Kasper A."'

2. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Drewes, A. Mohr, Haas, S.L., Hoyer, B.F., Hampe, J., Hinrichs, C. Noreen, Lerch, M.M., Aghdassi, A.A., Grote, T., Heuser, D.J., Ignatavicius, P., Malecka-Panas, E., Domínguez-Muñoz, J.E., López-Serrano, A., Auriemma, F., Oracz, G., Duman, D., Gubergrits, N., Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Dagna, Lorenzo, Cahen, Djuna L., Bordin, Dmitry, Rebours, Vinciane, Mayerle, Julia, Kahraman, Alisan, Rasch, Sebastian, Culver, Emma, Kleger, Alexander, Martínez-Moneo, Emma, Røkke, Ola, Hucl, Tomas, Olesen, Søren S., Bruno, Marco J., Della-Torre, Emanuel, Beuers, Ulrich, Löhr, J.-Matthias, and Rosendahl, Jonas

Published
2024
Full Text
View/download PDF

4. Intraductal Papillary Mucinous Neoplasms in High-Risk Individuals: Incidence, Growth Rate, and Malignancy Risk

Author

Overbeek, Kasper A., Koopmann, Brechtje D.M., Levink, Iris J.M., Tacelli, Matteo, Erler, Nicole S., Arcidiacono, Paolo Giorgio, Ausems, Margreet G.E., Wagner, Anja, van Eijck, Casper H., Groot Koerkamp, Bas, Busch, Olivier R., Besselink, Marc G., van der Vlugt, Manon, van Driel, Lydi M.J.W., Fockens, Paul, Vleggaar, Frank P., Poley, Jan-Werner, Capurso, Gabriele, Cahen, Djuna L., and Bruno, Marco J.

Published
2024
Full Text
View/download PDF

5. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery

Author

Paiella, Salvatore, Secchettin, Erica, Lionetto, Gabriella, Archibugi, Livia, Azzolina, Danila, Casciani, Fabio, Simeone, Diane M., Overbeek, Kasper A., Goggins, Michael, Farrell, James, Ponz de Leon Pisani, Ruggero, Tridenti, Maddalena, Corciulo, Maria Assunta, Malleo, Giuseppe, Arcidiacono, Paolo Giorgio, Falconi, Massimo, Gregori, Dario, Bassi, Claudio, Salvia, Roberto, and Capurso, Gabriele

Published
2024
Full Text
View/download PDF

6. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals

Author

Overbeek, Kasper A., Goggins, Michael G., Dbouk, Mohamad, Levink, Iris J.M., Koopmann, Brechtje D.M., Chuidian, Miguel, Konings, Ingrid C.A.W., Paiella, Salvatore, Earl, Julie, Fockens, Paul, Gress, Thomas M., Ausems, Margreet G.E.M., Poley, Jan-Werner, Thosani, Nirav C., Half, Elizabeth, Lachter, Jesse, Stoffel, Elena M., Kwon, Richard S., Stoita, Alina, Kastrinos, Fay, Lucas, Aimee L., Syngal, Sapna, Brand, Randall E., Chak, Amitabh, Carrato, Alfredo, Vleggaar, Frank P., Bartsch, Detlef K., van Hooft, Jeanin E., Cahen, Djuna L., Canto, Marcia Irene, and Bruno, Marco J.

Published
2022
Full Text
View/download PDF

8. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., primary, Poulsen, Jakob L., additional, Lanzillotta, Marco, additional, Vinge-Holmquist, Olof, additional, Macinga, Peter, additional, Demirci, A. Fatih, additional, Sindhunata, Daniko P., additional, Backhus, Johanna, additional, Algül, Hana, additional, Buijs, Jorie, additional, Levy, Philippe, additional, Kiriukova, Mariia, additional, Goni, Elisabetta, additional, Hollenbach, Marcus, additional, Miksch, Rainer C., additional, Kunovsky, Lumir, additional, Vujasinovic, Miroslav, additional, Nikolic, Sara, additional, Dickerson, Luke, additional, Hirth, Michael, additional, Neurath, Markus F., additional, Zumblick, Malte, additional, Vila, Josephine, additional, Jalal, Mustafa, additional, Beyer, Georg, additional, Frost, Fabian, additional, Carrara, Silvia, additional, Kala, Zdenek, additional, Jabandziev, Petr, additional, Sisman, Gurhan, additional, Akyuz, Filiz, additional, Capurso, Gabriele, additional, Falconi, Massimo, additional, Arlt, Alexander, additional, Vleggaar, Frank P., additional, Barresi, Luca, additional, Greenhalf, Bill, additional, Czakó, László, additional, Hegyi, Peter, additional, Hopper, Andrew, additional, Nayar, Manu K., additional, Gress, Thomas M., additional, Vitali, Francesco, additional, Schneider, Alexander, additional, Halloran, Chris M., additional, Trna, Jan, additional, Okhlobystin, Alexey V., additional, Dagna, Lorenzo, additional, Cahen, Djuna L., additional, Bordin, Dmitry, additional, Rebours, Vinciane, additional, Mayerle, Julia, additional, Kahraman, Alisan, additional, Rasch, Sebastian, additional, Culver, Emma, additional, Kleger, Alexander, additional, Martínez-Moneo, Emma, additional, Røkke, Ola, additional, Hucl, Tomas, additional, Olesen, Søren S., additional, Bruno, Marco J., additional, Della-Torre, Emanuel, additional, Beuers, Ulrich, additional, Löhr, J.-Matthias, additional, Rosendahl, Jonas, additional, Drewes, A. Mohr, additional, Haas, S.L., additional, Hoyer, B.F., additional, Hampe, J., additional, Hinrichs, C. Noreen, additional, Lerch, M.M., additional, Aghdassi, A.A., additional, Grote, T., additional, Heuser, D.J., additional, Ignatavicius, P., additional, Malecka-Panas, E., additional, Domínguez-Muñoz, J.E., additional, López-Serrano, A., additional, Auriemma, F., additional, Oracz, G., additional, Duman, D., additional, and Gubergrits, N., additional

Published
2024
Full Text
View/download PDF

9. Pancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2Apathogenic variant

Author

Klatte, Derk C. F., Meziani, Jihane, Cahen, Djuna L., Diepen, Merel, Bruno, Marco J., Leerdam, Monique E., Dekker, Friedo W., Hooft, Jeanin E., Onnekink, Anke M., Potjer, Thomas P., Levink, Iris J. M., Overbeek, Kasper A., Vleggaar, Frank P., and Voermans, Rogier P.

Abstract

Individuals carrying a germline CDKN2Apathogenic variant (PV) are at a high risk of developing pancreatic ductal adenocarcinoma. Risk stratification could allow tailored surveillance. To develop a Fine‐Gray prediction model for the risk of PDAC in carriers of a CDKN2APV. Data from two large Dutch pancreatic cancer surveillance programs were used. A limited set of predictor variables were selected bsased on previous literature and the clinical expertise of the study group. A total of 506 CDKN2APV carriers were included, among whom we showed a substantial lifetime risk of PDAC (23%). The model identifies having a first‐degree relative with PDAC (B= 0.7256) and a history of smoking (B= 0.4776) as significant risk factors. However, the model shows limited discrimination (c‐statistic 0.64) and calibration. Our study highlights the high lifetime risk of PDAC in carriers of a CDKN2APV. While identifying significant risk factors such as family history of PDAC and smoking, our prediction model shows limited precision, highlighting the need for additional factors such as biomarkers to improve its clinical utility for tailored surveillance of high‐risk individuals.

Published
2024
Full Text
View/download PDF

10. Intraductal papillary mucinous neoplasms in high-risk individuals:incidence, growth rate, and malignancy risk

Author

Overbeek, Kasper A, Koopmann, Brechtje D M, Levink, Iris J M, Tacelli, Matteo, Erler, Nicole S, Arcidiacono, Paolo Giorgio, Ausems, Margreet G E, Wagner, Anja, van Eijck, Casper H, Koerkamp, Bas Groot, Busch, Olivier R, Besselink, Marc G, van der Vlugt, Manon, van Driel, Lydi M J W, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, Capurso, Gabriele, Cahen, Djuna L, Bruno, Marco J, Overbeek, Kasper A, Koopmann, Brechtje D M, Levink, Iris J M, Tacelli, Matteo, Erler, Nicole S, Arcidiacono, Paolo Giorgio, Ausems, Margreet G E, Wagner, Anja, van Eijck, Casper H, Koerkamp, Bas Groot, Busch, Olivier R, Besselink, Marc G, van der Vlugt, Manon, van Driel, Lydi M J W, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, Capurso, Gabriele, Cahen, Djuna L, and Bruno, Marco J

Abstract

BACKGROUND AND AIMS: In high-risk individuals (HRIs), we aimed to assess the cumulative incidence of intraductal papillary mucinous neoplasms (IPMNs) and compare IPMN growth, neoplastic progression rate, and the value of growth as predictor for neoplastic progression to these in sporadic IPMNs.METHODS: We performed annual surveillance of Dutch HRIs, involving carriers of germline pathogenic variants (PV) and PV-negative familial pancreatic cancer (FPC) kindreds. HRIs with IPMNs were compared to Italian individuals without familial risk under surveillance for sporadic IPMNs.RESULTS: 457 HRIs were followed for 48 months (range 2-172); the estimated cumulative IPMN incidence was 46% (95%CI 28-64). In comparison to 442 controls, IPMNs in HRIs were more likely to grow ≥ 2.5 mm/year (31% versus 7%, P<0.001) and to develop worrisome features (32% versus 19%, P=0.010). PV carriers with IPMNs more often displayed neoplastic progression (n=3, 11%; versus n=6, 1%; P=0.011), while FPC kindreds did not (n=0, 0%; P=1.000). The malignancy risk in a PV carrier with an IPMN was 23% for growth rates ≥2.5 mm/year (n=13), 30% for ≥5 mm/year (n=10), and 60% for ≥10 mm/year (n=5).CONCLUSIONS: The cumulative incidence of IPMNs in HRIs is higher than previously reported in the general population. Compared to sporadic IPMNs, they have an increased growth rate. PV carriers with IPMNs are suggested to be at a higher malignancy risk. Intensive follow-up should be considered for PV carriers with an IPMN growing ≥2.5 mm/year, and surgical resection for those growing ≥5 mm/year.

Published
2024

11. Intraductal papillary mucinous neoplasms in high-risk individuals: incidence, growth rate, and malignancy risk

Author

Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Koopmann, Brechtje D M, Levink, Iris J M, Tacelli, Matteo, Erler, Nicole S, Arcidiacono, Paolo Giorgio, Ausems, Margreet G E, Wagner, Anja, van Eijck, Casper H, Koerkamp, Bas Groot, Busch, Olivier R, Besselink, Marc G, van der Vlugt, Manon, van Driel, Lydi M J W, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, Capurso, Gabriele, Cahen, Djuna L, Bruno, Marco J, Dutch Familial Pancreatic Cancer Surveillance Study work group, Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Koopmann, Brechtje D M, Levink, Iris J M, Tacelli, Matteo, Erler, Nicole S, Arcidiacono, Paolo Giorgio, Ausems, Margreet G E, Wagner, Anja, van Eijck, Casper H, Koerkamp, Bas Groot, Busch, Olivier R, Besselink, Marc G, van der Vlugt, Manon, van Driel, Lydi M J W, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, Capurso, Gabriele, Cahen, Djuna L, Bruno, Marco J, and Dutch Familial Pancreatic Cancer Surveillance Study work group

Published
2024

12. Type 1 Autoimmune Pancreatitis in Europe:Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Cahen, Djuna L., Bruno, Marco J., Haas, S. L., Overbeek, Kasper A., Poulsen, Jakob L., Lanzillotta, Marco, Vinge-Holmquist, Olof, Macinga, Peter, Demirci, A. Fatih, Sindhunata, Daniko P., Backhus, Johanna, Algül, Hana, Buijs, Jorie, Levy, Philippe, Kiriukova, Mariia, Goni, Elisabetta, Hollenbach, Marcus, Miksch, Rainer C., Kunovsky, Lumir, Vujasinovic, Miroslav, Nikolic, Sara, Dickerson, Luke, Hirth, Michael, Neurath, Markus F., Zumblick, Malte, Vila, Josephine, Jalal, Mustafa, Beyer, Georg, Frost, Fabian, Carrara, Silvia, Kala, Zdenek, Jabandziev, Petr, Sisman, Gurhan, Akyuz, Filiz, Capurso, Gabriele, Falconi, Massimo, Arlt, Alexander, Vleggaar, Frank P., Barresi, Luca, Greenhalf, Bill, Czakó, László, Hegyi, Peter, Hopper, Andrew, Nayar, Manu K., Gress, Thomas M., Vitali, Francesco, Schneider, Alexander, Halloran, Chris M., Trna, Jan, Okhlobystin, Alexey V., Cahen, Djuna L., Bruno, Marco J., and Haas, S. L.

Abstract

Background & Aims: Autoimmune pancreatitis (AIP) is an immune-mediated disease of the pancreas with distinct pathophysiology and manifestations. Our aims were to characterize type 1 AIP in a large pan-European cohort and study the effectiveness of current treatment regimens. Methods: We retrospectively analyzed adults diagnosed since 2005 with type 1 or not-otherwise-specified AIP in 42 European university hospitals. Type 1 AIP was uniformly diagnosed using specific diagnostic criteria. Patients with type 2 AIP and those who had undergone pancreatic surgery were excluded. The primary end point was complete remission, defined as the absence of clinical symptoms and resolution of the index radiologic pancreatic abnormalities attributed to AIP. Results: We included 735 individuals with AIP (69% male; median age, 57 years; 85% White). Steroid treatment was started in 634 patients, of whom 9 (1%) were lost to follow-up. The remaining 625 had a 79% (496/625) complete, 18% (111/625) partial, and 97% (607/625) cumulative remission rate, whereas 3% (18/625) did not achieve remission. No treatment was given in 95 patients, who had a 61% complete (58/95), 19% partial (18/95), and 80% cumulative (76/95) spontaneous remission rate. Higher (≥0.4 mg/kg/day) corticosteroid doses were no more effective than lower (<0.4 mg/kg/day) doses (odds ratio, 0.428; 95% confidence interval, 0.054–3.387) and neither was a starting dose duration >2 weeks (odds ratio, 0.908; 95% confidence interval, 0.818–1.009). Elevated IgG4 levels were independently associated with a decreased chance of complete remission (odds ratio, 0.639; 95% confidence interval, 0.427–0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid-tapering duration, induction treatment duration, and total cumulative dose. Conclusions: Patients with type 1 AIP and elevated IgG4 level may need closer monitoring. For remission induction, a starting dose

Published
2024

13. Pancreatic cyst surveillance imposes low psychological burden

Author

Bruno, M.J., Cahen, D.L., van Riet, P.A., Overbeek, K.A., Levink, I.J.M., Koopmann, B., Besselink, M.G.H., del Chiaro, M., Lerch, M.M., Wallace, M.B., van Ballegooijen, M., Biermann, K., Bleiker, E.M.A., Bollen, T.H.L., Fockens, P., de Kok, I.M.C.M., Looijenga, L.H.J., Peppelenbosch, M.P., Verhagen-Oldenampsen, J.H.E., Arcidiacono, P.G., Capurso, G., Bergmann, J., van Berkel, A., Beyer, G., Bijlsma, R., Braat, H., Carrara, S., Czakó, L., van Erp-van der Steen, H., Ganesh, S., van Geenen, E., Gonda, T., Hoge, C., Honkoop, P., van Hooft, J.E., Jansen, J., Larghi, A., van Leeuwenburgh, I., Laukkarinen, J., Lelyveld, N., Lerch, M., di Marco, M.C., Ricci, C., Casadei, R., Rau, E.P., Perk, L., Polkowski, M., Pukitits, A., Quispel, R., Radenkovic, D., Seicean, A., Schwartz, T., Schoon, E.J., van Soest, E., Tan, A., Venneman, N.G., Vos, P., Voorburg, A., van der Waaij, L.A., Wijkerslooth, L.R.H., Zerboni, G., della Fave, G., Zonderhuis, B., Overbeek, Kasper A., Kamps, Anne, van Riet, Priscilla A., Di Marco, Mariacristina, Zerboni, Giulia, van Hooft, Jeanin E., Carrara, Silvia, Ricci, Claudio, Gonda, Tamas A., Schoon, Erik, Polkowski, Marcin, Beyer, Georg, Honkoop, Pieter, van der Waaij, Laurens A., Casadei, Riccardo, Capurso, Gabriele, Erler, Nicole S., Bruno, Marco J., Bleiker, Eveline M.A., and Cahen, Djuna L.

Published
2019
Full Text
View/download PDF

14. Small cyst size and slow growth rate are soothing features in individuals with pancreatic cysts undergoing surveillance

Author

Levink, Iris, primary, Koopmann, Brechtje, additional, Jaarsma, Sanne, additional, van Riet, Priscilla, additional, Overbeek, Kasper, additional, Meziani, Jihane, additional, Sprij, Marloes, additional, Gorris, Myrte, additional, Van Hooft, Jeanin, additional, Casadei, Riccardo, additional, Ingaldi, Carlo, additional, Wallace, Michael, additional, Hoogenboom, Sanne, additional, Honkoop, Pieter, additional, Polkowski, Marcin, additional, Carrara, Silvia, additional, Schoon, Erik, additional, Gemma, Rossi, additional, van der Waaij, Laurens, additional, Beyer, Georg, additional, Bergmann, Jilling, additional, Pando, Elizabeth, additional, Venneman, Niels, additional, Laukkarinen, Johanna, additional, Berkel, Anne-Marie van, additional, Van Vilsteren, Frederike, additional, Schwartz, Thijs, additional, Azopardi, Neville, additional, Hoge, Chantal, additional, van Soest, Ellert, additional, Smits, Marianne, additional, Quispel, Rutger, additional, Vos, Patrick, additional, Tan, Adriaan, additional, Czacko, Laszlo, additional, Leeuwenburgh, Ivonne, additional, Bruno, Marco, additional, and Cahen, Djuna, additional

Published
2023
Full Text
View/download PDF

16. Pancreatic cancer surveillance

Author

Overbeek, Kasper, Bruno, Marco, Cahen, Djuna, and Gastroenterology & Hepatology

Subjects
SDG 3 - Good Health and Well-being
Abstract

This thesis describes scientific research on several aspects of pancreatic cancer surveillance. The goal of surveillance is to detect the disease in an early stage. The thesis consists of ten studies that are divided over three parts.

Published
2023

18. The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program

Author

Levink, Iris J.M., Jaarsma, Sanne C., Koopmann, Brechtje D.M., van Riet, Priscilla A., Overbeek, Kasper A., Meziani, Jihane, Sprij, Marloes L.J.A., Casadei, Riccardo, Ingaldi, Carlo, Polkowski, Marcin, Engels, Megan M.L., van der Waaij, Laurens A., Carrara, Silvia, Pando, Elizabeth, Vornhülz, Marlies, Honkoop, Pieter, Schoon, Erik J., Laukkarinen, Johanna, Bergmann, Jilling F., Rossi, Gemma, van Vilsteren, Frederike G.I., van Berkel, Anne Marie, Tabone, Trevor, Schwartz, Matthijs P., Tan, Adriaan C.I.T.L., van Hooft, Jeanin E., Quispel, Rutger, van Soest, Ellert, Czacko, Laszlo, Bruno, Marco J., Cahen, Djuna L., Levink, Iris J.M., Jaarsma, Sanne C., Koopmann, Brechtje D.M., van Riet, Priscilla A., Overbeek, Kasper A., Meziani, Jihane, Sprij, Marloes L.J.A., Casadei, Riccardo, Ingaldi, Carlo, Polkowski, Marcin, Engels, Megan M.L., van der Waaij, Laurens A., Carrara, Silvia, Pando, Elizabeth, Vornhülz, Marlies, Honkoop, Pieter, Schoon, Erik J., Laukkarinen, Johanna, Bergmann, Jilling F., Rossi, Gemma, van Vilsteren, Frederike G.I., van Berkel, Anne Marie, Tabone, Trevor, Schwartz, Matthijs P., Tan, Adriaan C.I.T.L., van Hooft, Jeanin E., Quispel, Rutger, van Soest, Ellert, Czacko, Laszlo, Bruno, Marco J., and Cahen, Djuna L.

Abstract

Background:Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population. Methods: The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months.Results: Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1–13, p = 0.03). Conclusions: In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to imp

Published
2023

19. Intraductal Papillary Mucinous Neoplasms in High-Risk Individuals: Incidence, Growth Rate, and Malignancy Risk

Author

Overbeek, Kasper A., primary, Koopmann, Brechtje D.M., additional, Levink, Iris J.M., additional, Tacelli, Matteo, additional, Erler, Nicole S., additional, Arcidiacono, Paolo Giorgio, additional, Ausems, Margreet G.E., additional, Wagner, Anja, additional, van Eijck, Casper H., additional, Groot Koerkamp, Bas, additional, Busch, Olivier R., additional, Besselink, Marc G., additional, van der Vlugt, Manon, additional, van Driel, Lydi M.J.W., additional, Fockens, Paul, additional, Vleggaar, Frank P., additional, Poley, Jan-Werner, additional, Capurso, Gabriele, additional, Cahen, Djuna L., additional, and Bruno, Marco J., additional

Published
2023
Full Text
View/download PDF

21. Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Author

Overbeek, Kasper A., primary, Poulsen, J., additional, Lanzillotta, M., additional, Vinge-Holmquist, O., additional, Macinga, P., additional, Demirci, A., additional, Sindhunata, D., additional, Backhus, J., additional, Algül, H., additional, Buijs, J., additional, Levy, P., additional, Kiriukova, M., additional, Goni, E., additional, Hollenbach, M., additional, Miksch, R., additional, Kunovský, L., additional, Vujasinovic, M., additional, Nikolic, S., additional, Dickerson, L., additional, Hirth, M., additional, Neurath, M., additional, Zumblick, M., additional, Vila, J., additional, Jalal, M., additional, Beyer, G., additional, Frost, F., additional, Carrara, S., additional, Kala, Z., additional, Jabandžiev, P., additional, Sisman, G., additional, Akyuz, F., additional, Capurso, G., additional, Falconi, M., additional, Arlt, A., additional, Vleggaar, F., additional, Barresi, L., additional, Greenhalf, B., additional, Czakó, L., additional, Hegyi, P., additional, Hopper, A., additional, Nayar, M., additional, Gress, T., additional, Vitali, F., additional, Schneider, A., additional, Halloran, C., additional, Trna, J., additional, Okhlobystin, A., additional, Dagna, L., additional, Cahen, D., additional, Bordin, D., additional, Rebours, V., additional, Mayerle, J., additional, Kahraman, A., additional, Rasch, S., additional, Culver, E., additional, Kleger, A., additional, Martínez-Moneo, E., additional, Røkke, O., additional, Hucl, T., additional, Olesen, S., additional, Bruno, M., additional, Della-Torre, E., additional, Beuers, U., additional, Löhr, J., additional, and Rosendahl, J., additional

Published
2022
Full Text
View/download PDF

22. International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression

Author

Overbeek, Kasper A., van Leeuwen, Nikki, Tacelli, Matteo, Anwar, Muhammad S., Yousaf, Muhammad N., Chhoda, Ankit, Arcidiacono, Paolo Giorgio, Gonda, Tamas A., Wallace, Michael B., Capurso, Gabriele, Farrell, James J., Cahen, Djuna L., Bruno, Marco J., Overbeek, Kasper A., van Leeuwen, Nikki, Tacelli, Matteo, Anwar, Muhammad S., Yousaf, Muhammad N., Chhoda, Ankit, Arcidiacono, Paolo Giorgio, Gonda, Tamas A., Wallace, Michael B., Capurso, Gabriele, Farrell, James J., Cahen, Djuna L., and Bruno, Marco J.

Abstract

Background: Identifying branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) at lowest risk of progression may allow for a reduced intensity of surveillance. Objective: We aimed to externally validate the previously developed Dutch-American Risk stratification Tool (DART-1; https://rtools.mayo.edu/DART/), which identifies cysts at low risk of developing worrisome features (WFs) or high-risk stigmata (HRS). Methods: Three prospective cohorts of individuals under surveillance for BD-IPMNs were combined, independent from the original development cohort. We assessed the performance (discrimination and calibration) of DART-1, a multivariable Cox-proportional logistic regression model with five predictors for the development of WFs or HRS. Results: Of 832 individuals (mean age 77 years, SD 11.5) under surveillance for a median of 40 months (IQR 44), 163 (20%) developed WFs or HRS. DART-1's discriminative ability (C-statistic 0.68) was similar to that in the development cohort (0.64–0.72) and showed moderate calibration. DART-1 adequately estimated the risk for patients in the middle risk quintile, and slightly underestimated it in the lowest quintiles. Their range of predicted versus observed 3-year risk was 0%–0% versus 0%–3.7% for Q1; 0.3%–0.4% versus 3%–11% for Q2; and 2.6%–3% versus 2.4%–9.8% for Q3. The development of WFs or HRS was associated with pancreatic cancer (p < 0.001). Vice versa, in absence of WFs or HRS, the risk of malignancy was low (0.3%). Conclusions: The performance of DART-1 to predict the development of WFs or HRS in BD-IPMN was validated in an external international cohort, with a discriminative ability equal as in the development cohort. Risk estimations were most accurate for patients with BD-IPMNs in the middle risk quintile and slightly underestimated in the lowest quintiles.

Published
2022

23. Long-term yield of pancreatic cancer surveillance in high-risk individuals

Author

Overbeek, Kasper A., Levink, Iris J. M., Koopmann, Brechtje D. M., Harinck, Femme, Konings, Ingrid C. A. W., Ausems, Margreet G. E. M., Wagner, Anja, Fockens, Paul, van Eijck, Casper H., Koerkamp, Bas Groot, Busch, Olivier R. C., Besselink, Marc G., Bastiaansen, Barbara A. J., van Driel, Lydi M. J. W., Erler, Nicole S., Vleggaar, Frank P., Poley, Jan-Werner, Cahen, Djuna L., van Hooft, Jeanin E., Bruno, Marco J., Overbeek, Kasper A., Levink, Iris J. M., Koopmann, Brechtje D. M., Harinck, Femme, Konings, Ingrid C. A. W., Ausems, Margreet G. E. M., Wagner, Anja, Fockens, Paul, van Eijck, Casper H., Koerkamp, Bas Groot, Busch, Olivier R. C., Besselink, Marc G., Bastiaansen, Barbara A. J., van Driel, Lydi M. J. W., Erler, Nicole S., Vleggaar, Frank P., Poley, Jan-Werner, Cahen, Djuna L., van Hooft, Jeanin E., and Bruno, Marco J.

Abstract

Objective We aimed to determine the long-term yield of pancreatic cancer surveillance in hereditary predisposed high-risk individuals.Design From 2006 to 2019, we prospectively enrolled asymptomatic individuals with an estimated 10% or greater lifetime risk of pancreatic ductal adenocarcinoma (PDAC) after obligatory evaluation by a clinical geneticist and genetic testing, and subjected them to annual surveillance with both endoscopic ultrasonography (EUS) and MRI/cholangiopancreatography (MRI/MRCP) at each visit.Results 366 individuals (201 mutation-negative familial pancreatic cancer (FPC) kindreds and 165 PDAC susceptibility gene mutation carriers; mean age 54 years, SD 9.9) were followed for 63 months on average (SD 43.2). Ten individuals developed PDAC, of which four presented with a symptomatic interval carcinoma and six underwent resection. The cumulative PDAC incidence was 9.3% in the mutation carriers and 0% in the FPC kindreds (p<0.001). Median PDAC survival was 18 months (range 1-32). Surgery was performed in 17 individuals (4.6%), whose pathology revealed 6 PDACs (3 T1N0M0), 7 low-grade precursor lesions, 2 neuroendocrine tumours <2 cm, 1 autoimmune pancreatitis and in 1 individual no abnormality. There was no surgery-related mortality. EUS detected more solid lesions than MRI/MRCP (100% vs 22%, p<0.001), but less cystic lesions (42% vs 83%, p<0.001).Conclusion The diagnostic yield of PDAC was substantial in established high-risk mutation carriers, but non-existent in the mutation-negative proven FPC kindreds. Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with EUS outperforming MRI/MRCP. Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.

Published
2022

24. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals

Author

Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Goggins, Michael G, Dbouk, Mohamad, Levink, Iris J M, Koopmann, Brechtje D M, Chuidian, Miguel, Konings, Ingrid C A W, Paiella, Salvatore, Earl, Julie, Fockens, Paul, Gress, Thomas M, Ausems, Margreet G E M, Poley, Jan-Werner, Thosani, Nirav C, Half, Elizabeth, Lachter, Jesse, Stoffel, Elena M, Kwon, Richard S, Stoita, Alina, Kastrinos, Fay, Lucas, Aimee L, Syngal, Sapna, Brand, Randall E, Chak, Amitabh, Carrato, Alfredo, Vleggaar, Frank P, Bartsch, Detlef K, van Hooft, Jeanin E, Cahen, Djuna L, Canto, Marcia Irene, Bruno, Marco J, International Cancer of the Pancreas Screening Consortium, Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Goggins, Michael G, Dbouk, Mohamad, Levink, Iris J M, Koopmann, Brechtje D M, Chuidian, Miguel, Konings, Ingrid C A W, Paiella, Salvatore, Earl, Julie, Fockens, Paul, Gress, Thomas M, Ausems, Margreet G E M, Poley, Jan-Werner, Thosani, Nirav C, Half, Elizabeth, Lachter, Jesse, Stoffel, Elena M, Kwon, Richard S, Stoita, Alina, Kastrinos, Fay, Lucas, Aimee L, Syngal, Sapna, Brand, Randall E, Chak, Amitabh, Carrato, Alfredo, Vleggaar, Frank P, Bartsch, Detlef K, van Hooft, Jeanin E, Cahen, Djuna L, Canto, Marcia Irene, Bruno, Marco J, and International Cancer of the Pancreas Screening Consortium

Published
2022

25. The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program

Author

Levink, Iris J. M., Jaarsma, Sanne C., Koopmann, Brechtje D. M., Riet, Priscilla A., Overbeek, Kasper A., Meziani, Jihane, Sprij, Marloes L. J. A., Casadei, Riccardo, Ingaldi, Carlo, Polkowski, Marcin, Engels, Megan M. L., Waaij, Laurens A., Carrara, Silvia, Pando, Elizabeth, Vornhülz, Marlies, Honkoop, Pieter, Schoon, Erik J., Laukkarinen, Johanna, Bergmann, Jilling F., Rossi, Gemma, Vilsteren, Frederike G. I., Berkel, Anne‐Marie, Tabone, Trevor, Schwartz, Matthijs P., Tan, Adriaan C. I. T. L., Hooft, Jeanin E., Quispel, Rutger, Soest, Ellert, Czacko, Laszlo, Bruno, Marco J., and Cahen, Djuna L.

Abstract

Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population. The PACYFIC‐registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow‐up of 12 months. Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow‐up of 25 months (IQR 24, 1966 visits), 29 participants developed high‐grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow‐up (42%) than those without an elevated CA19.9 (27%; p< 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1–13, p= 0.03). In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false‐positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.

Published
2023
Full Text
View/download PDF

26. International external validation of a stratification tool to identify branch‐duct intraductal papillary mucinous neoplasms at lowest risk of progression

Author

Overbeek, Kasper A., primary, van Leeuwen, Nikki, additional, Tacelli, Matteo, additional, Anwar, Muhammad S., additional, Yousaf, Muhammad N., additional, Chhoda, Ankit, additional, Arcidiacono, Paolo Giorgio, additional, Gonda, Tamas A., additional, Wallace, Michael B., additional, Capurso, Gabriele, additional, Farrell, James J., additional, Cahen, Djuna L., additional, and Bruno, Marco J., additional

Published
2022
Full Text
View/download PDF

27. 185 DISCOVERY OF A SERUM N-GLYCAN PANEL FOR EARLY DETECTION OF PANCREATIC CANCER IN A HIGH-RISK SURVEILLANCE COHORT

Author

Levink, Iris J., primary, Klatte, Derk C.F., additional, Hanna-Sawires, R.G., additional, van der Burgt, Yuri E.M., additional, Overbeek, Kasper A., additional, Koopmann, Brechtje D., additional, Cahen, D.L., additional, Fuhler, Gwenny, additional, Vleggaar, Frank P., additional, Wuhrer, Manfred, additional, Tollenaar, Rob, additional, Vasen, Hans F., additional, Bruno, Marco J., additional, and Mesker, Wilma E., additional

Published
2021
Full Text
View/download PDF

28. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants

Author

Overbeek, Kasper A., Rodríguez-Girondo, Mar D.M., Wagner, Anja, Van Der Stoep, Nienke, Van Den Akker, Peter C., Oosterwijk, Jan C., Van Os, Theo A., Van Der Kolk, Lizet E., Vasen, Hans F.A., Hes, Frederik J., Cahen, Djuna L., Bruno, Marco J., Potjer, Thomas P., Overbeek, Kasper A., Rodríguez-Girondo, Mar D.M., Wagner, Anja, Van Der Stoep, Nienke, Van Den Akker, Peter C., Oosterwijk, Jan C., Van Os, Theo A., Van Der Kolk, Lizet E., Vasen, Hans F.A., Hes, Frederik J., Cahen, Djuna L., Bruno, Marco J., and Potjer, Thomas P.

Abstract

Background Pathogenic variants in the CDKN2A gene are generally associated with the development of melanoma and pancreatic ductal adenocarcinoma (PDAC), but specific genotype-phenotype correlations might exist and the extent of PDAC risk is not well established for many variants. Methods Using the Dutch national familial melanoma database, we identified all families with a pathogenic CDKN2A variant and investigated the occurrence of PDAC within these families. We also estimated the standardised incidence ratio and lifetime PDAC risk for carriers of a highly prevalent variant in these families. Results We identified 172 families in which 649 individuals carried 15 different pathogenic variants. The most prevalent variant was the founder mutation c.225_243del (p16-Leiden, 484 proven carriers). Second most prevalent was c.67G>C (55 proven carriers). PDAC developed in 95 of 163 families (58%, including 373 of 629 proven carriers) harbouring a variant with an effect on the p16INK4a protein, whereas PDAC did not occur in the 9 families (20 proven carriers) with a variant affecting only p14ARF. In the c.67G>C families, PDAC occurred in 12 of the 251 (5%) persons at risk. The standardised incidence ratio was 19.1 (95% CI 8.3 to 33.6) and the cumulative PDAC incidence at age 75 years (lifetime risk) was 19% (95% CI 7.5% to 30.1%). Conclusions Our results support the notion that pathogenic CDKN2A variants affecting the p16INK4a protein, including c.67G>C, are associated with increased PDAC risk and carriers of such variants should be offered pancreatic cancer surveillance. There is no clinical evidence that impairment of only the p14ARF protein leads to an increased PDAC risk.

Published
2021

29. Long-term yield of pancreatic cancer surveillance in high-risk individuals

Author

Overbeek, Kasper A, primary, Levink, Iris J M, additional, Koopmann, Brechtje D M, additional, Harinck, Femme, additional, Konings, Ingrid C A W, additional, Ausems, Margreet G E M, additional, Wagner, Anja, additional, Fockens, Paul, additional, van Eijck, Casper H, additional, Groot Koerkamp, Bas, additional, Busch, Olivier R C, additional, Besselink, Marc G, additional, Bastiaansen, Barbara A J, additional, van Driel, Lydi M J W, additional, Erler, Nicole S, additional, Vleggaar, Frank P, additional, Poley, Jan-Werner, additional, Cahen, Djuna L, additional, van Hooft, Jeanin E, additional, and Bruno, Marco J, additional

Published
2021
Full Text
View/download PDF

31. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants

Author

Overbeek, Kasper A, primary, Rodríguez-Girondo, Mar DM, additional, Wagner, Anja, additional, van der Stoep, Nienke, additional, van den Akker, Peter C, additional, Oosterwijk, Jan C, additional, van Os, Theo A, additional, van der Kolk, Lizet E, additional, Vasen, Hans F A, additional, Hes, Frederik J, additional, Cahen, Djuna L, additional, Bruno, Marco J, additional, and Potjer, Thomas P, additional

Published
2020
Full Text
View/download PDF

34. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance

Author

Child Health, Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Cahen, Djuna L, Kamps, Anne, Konings, Ingrid C A W, Harinck, Femme, Kuenen, Marianne A, Koerkamp, Bas Groot, Besselink, Marc G, van Eijck, Casper H, Wagner, Anja, Ausems, Margreet G E, van der Vlugt, Manon, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, van Hooft, Jeanin E, Bleiker, Eveline M A, Bruno, Marco J, Dutch Familial Pancreatic Cancer Surveillance Study Group, Child Health, Cancer, Genetica Klinische Genetica, MS MDL 1, Overbeek, Kasper A, Cahen, Djuna L, Kamps, Anne, Konings, Ingrid C A W, Harinck, Femme, Kuenen, Marianne A, Koerkamp, Bas Groot, Besselink, Marc G, van Eijck, Casper H, Wagner, Anja, Ausems, Margreet G E, van der Vlugt, Manon, Fockens, Paul, Vleggaar, Frank P, Poley, Jan-Werner, van Hooft, Jeanin E, Bleiker, Eveline M A, Bruno, Marco J, and Dutch Familial Pancreatic Cancer Surveillance Study Group

Published
2020

35. Pancreatic cyst surveillance imposes low psychological burden

Author

Overbeek, Kasper A., primary, Kamps, Anne, additional, van Riet, Priscilla A., additional, Di Marco, Mariacristina, additional, Zerboni, Giulia, additional, van Hooft, Jeanin E., additional, Carrara, Silvia, additional, Ricci, Claudio, additional, Gonda, Tamas A., additional, Schoon, Erik, additional, Polkowski, Marcin, additional, Beyer, Georg, additional, Honkoop, Pieter, additional, van der Waaij, Laurens A., additional, Casadei, Riccardo, additional, Capurso, Gabriele, additional, Erler, Nicole S., additional, Bruno, Marco J., additional, Bleiker, Eveline M.A., additional, Cahen, Djuna L., additional, Bruno, M.J., additional, Cahen, D.L., additional, van Riet, P.A., additional, Overbeek, K.A., additional, Levink, I.J.M., additional, Koopmann, B., additional, Besselink, M.G.H., additional, del Chiaro, M., additional, Lerch, M.M., additional, Wallace, M.B., additional, van Ballegooijen, M., additional, Biermann, K., additional, Bleiker, E.M.A., additional, Bollen, T.H.L., additional, Fockens, P., additional, de Kok, I.M.C.M., additional, Looijenga, L.H.J., additional, Peppelenbosch, M.P., additional, Verhagen-Oldenampsen, J.H.E., additional, Arcidiacono, P.G., additional, Capurso, G., additional, Bergmann, J., additional, van Berkel, A., additional, Beyer, G., additional, Bijlsma, R., additional, Braat, H., additional, Carrara, S., additional, Czakó, L., additional, van Erp-van der Steen, H., additional, Ganesh, S., additional, van Geenen, E., additional, Gonda, T., additional, Hoge, C., additional, Honkoop, P., additional, van Hooft, J.E., additional, Jansen, J., additional, Larghi, A., additional, van Leeuwenburgh, I., additional, Laukkarinen, J., additional, Lelyveld, N., additional, Lerch, M., additional, di Marco, M.C., additional, Ricci, C., additional, Casadei, R., additional, Rau, E.P., additional, Perk, L., additional, Polkowski, M., additional, Pukitits, A., additional, Quispel, R., additional, Radenkovic, D., additional, Seicean, A., additional, Schwartz, T., additional, Schoon, E.J., additional, van Soest, E., additional, Tan, A., additional, Venneman, N.G., additional, Vos, P., additional, Voorburg, A., additional, van der Waaij, L.A., additional, Wijkerslooth, L.R.H., additional, Zerboni, G., additional, della Fave, G., additional, and Zonderhuis, B., additional

Published
2019
Full Text
View/download PDF

36. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

Author

Goggins, Michael, primary, Overbeek, Kasper Alexander, additional, Brand, Randall, additional, Syngal, Sapna, additional, Del Chiaro, Marco, additional, Bartsch, Detlef K, additional, Bassi, Claudio, additional, Carrato, Alfredo, additional, Farrell, James, additional, Fishman, Elliot K, additional, Fockens, Paul, additional, Gress, Thomas M, additional, van Hooft, Jeanin E, additional, Hruban, R H, additional, Kastrinos, Fay, additional, Klein, Allison, additional, Lennon, Anne Marie, additional, Lucas, Aimee, additional, Park, Walter, additional, Rustgi, Anil, additional, Simeone, Diane, additional, Stoffel, Elena, additional, Vasen, Hans F A, additional, Cahen, Djuna L, additional, Canto, Marcia Irene, additional, and Bruno, Marco, additional

Published
2019
Full Text
View/download PDF

38. Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of progression

Author

Overbeek, Kasper A., primary, Alblas, Maaike, additional, Gausman, Valerie, additional, Kandel, Pujan, additional, Schweber, Adam B., additional, Brooks, Christian, additional, Van Riet, Priscilla A., additional, Wallace, Michael B., additional, Gonda, Tamas A., additional, Cahen, Djuna L., additional, and Bruno, Marco J., additional

Published
2019
Full Text
View/download PDF

39. Explorative Prospective Evaluation of Short-Term Subjective Effects of Hormonal Treatment in Trans People—Results from the European Network for the Investigation of Gender Incongruence

Author

van Dijk, Dennis, primary, Dekker, Marieke J.H.J., additional, Conemans, Elfi B., additional, Wiepjes, Chantal M., additional, de Goeij, Eva G.M., additional, Overbeek, Kasper A., additional, Fisher, Alessandra D., additional, den Heijer, Martin, additional, and T’Sjoen, Guy, additional

Published
2019
Full Text
View/download PDF

40. 12 Years of prospective pancreatic cancer surveillance: Results of the Dutch nationwide program in high-risk individuals

Author

Overbeek, Kasper, primary, Levink, Iris, additional, Konings, Ingrid, additional, Harinck, Femme, additional, Koopmann, Brechtje, additional, Ausems, Margreet, additional, Wagner, Anja, additional, Fockens, Paul, additional, Koerkamp, Bas Groot, additional, Besselink, Marc G., additional, van der Vlugt, Manon, additional, Vleggaar, Frank, additional, Poley, Jan-Werner, additional, Cahen, Djuna, additional, van Hooft, Jeanin E., additional, and Bruno, Marco J., additional

Published
2019
Full Text
View/download PDF

41. Updated international Cancer of the Pancreas Screening (CAPS) consortium guidelines on the management of patients with increased risk for familial pancreatic cancer

Author

Overbeek, Kasper, primary, Canto, Marcia Irene, additional, Bartsch, Detlef, additional, Brand, Randall, additional, Carrato, Alfredo, additional, Del Chiaro, Marco, additional, Farrell, James, additional, Fishman, Elliot, additional, Fockens, Paul, additional, Gress, Thomas, additional, van Hooft, Jeanin E., additional, Kastrinos, Fay, additional, Rustgi, Anil, additional, Syngal, Sapna, additional, Vasen, Hans, additional, Cahen, Djuna, additional, Bruno, Marco J., additional, and Goggins, Michael, additional

Published
2019
Full Text
View/download PDF

42. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance

Author

Overbeek, Kasper, primary, Cahen, Djuna, additional, Kamps, Anne, additional, Konings, Ingrid, additional, Harinck, Femme, additional, Kuenen, Marianne, additional, Koerkamp, Bas Groot, additional, Besselink, Marc G., additional, van Eijck, Casper, additional, Wagner, Anja, additional, Ausems, Margreet, additional, van der Vlugt, Manon, additional, Fockens, Paul, additional, Vleggaar, Frank, additional, Poley, Jan-Werner, additional, van Hooft, Jeanin E., additional, Bleiker, Eveline, additional, and Bruno, Marco J., additional

Published
2019
Full Text
View/download PDF

43. 41 – The Dutch American Risk Stratification Tool Predicts Well the Progression of Intraductal Papillary Mucinous Neoplasms Compared to Fukuoka, Aga and Esge Guidelines

Author

Ciofoaia, Victor, primary, Overbeek, Kasper A., additional, Alblas, Maaike, additional, Gausman, Valerie, additional, Kandel, Pujan, additional, Schweber, Adam B., additional, Brooks, Christian, additional, van Riet, Priscilla A., additional, Corral, Juan E., additional, Gonda, Tamas A., additional, Cahen, Djuna, additional, Bruno, Marco J., additional, and Wallace, Michael B., additional

Published
2019
Full Text
View/download PDF

44. Mo1374 – 12 Years of Prospective Pancreatic Cancer Surveillance: Results of the Dutch Nationwide Program in High-Risk Individuals

Author

Overbeek, Kasper A., primary, Levink, Iris J., additional, Konings, Ingrid C., additional, Harinck, Femme, additional, Koopmann, Brechtje D., additional, Ausems, Margreet G., additional, Wagner, Anja, additional, Fockens, Paul, additional, Koerkamp, B. Groot, additional, Besselink, Marc, additional, van der Vlugt, Manon, additional, Vleggaar, Frank P., additional, Poley, Jan-Werner, additional, Cahen, Djuna, additional, Van Hooft, Jeanin E., additional, and Bruno, Marco J., additional

Published
2019
Full Text
View/download PDF

45. Sa1365 – Patient-Reported Burden of Intensified Surveillance and Surgery in High-Risk Individuals Under Pancreatic Cancer Surveillance

Author

Overbeek, Kasper A., primary, Cahen, Djuna, additional, Kamps, Anne, additional, Konings, Ingrid C., additional, Harinck, Femme, additional, Kuenen, Marianne A., additional, Koerkamp, B. Groot, additional, Besselink, Marc, additional, Wagner, Anja, additional, Ausems, Margreet G., additional, van der Vlugt, Manon, additional, Fockens, Paul, additional, Vleggaar, Frank P., additional, Poley, Jan-Werner, additional, van Hooft, Jeanin E., additional, Bleiker, Eveline M., additional, and Bruno, Marco J., additional

Published
2019
Full Text
View/download PDF

46. Sa1350 – Updated International Cancer of the Pancreas Screening (CAPS) Consortium Guidelines on the Management of Patients with Increased Risk for Familial Pancreatic Cancer

Author

Overbeek, Kasper A., primary, Canto, Marcia I., additional, Bartsch, Detlef K., additional, Brand, Randall, additional, Carrato, Alfredo, additional, Del Chiaro, Marco, additional, Farrell, James J., additional, Fishman, Elliot K., additional, Fockens, Paul, additional, Gress, Thomas M., additional, van Hooft, Jeanin E., additional, Kastrinos, Fay, additional, Rustgi, Anil K., additional, Syngal, Sapna, additional, Vasen, Hans F., additional, Cahen, Djuna, additional, Bruno, Marco J., additional, and Goggins, Michael G., additional

Published
2019
Full Text
View/download PDF

48. Long-term yield of pancreatic cancer surveillance in high-risk individuals

Author

Overbeek, Kasper A, Levink, Iris J M, Koopmann, Brechtje D M, Harinck, Femme, Konings, Ingrid C A W, Ausems, Margreet G E M, Wagner, Anja, Fockens, Paul, van Eijck, Casper H, Groot Koerkamp, Bas, Busch, Olivier R C, Besselink, Marc G, Bastiaansen, Barbara A J, van Driel, Lydi M J W, Erler, Nicole S, Vleggaar, Frank P, Poley, Jan-Werner, Cahen, Djuna L, van Hooft, Jeanin E, and Bruno, Marco J

Abstract

ObjectiveWe aimed to determine the long-term yield of pancreatic cancer surveillance in hereditary predisposed high-risk individuals.DesignFrom 2006 to 2019, we prospectively enrolled asymptomatic individuals with an estimated 10% or greater lifetime risk of pancreatic ductal adenocarcinoma (PDAC) after obligatory evaluation by a clinical geneticist and genetic testing, and subjected them to annual surveillance with both endoscopic ultrasonography (EUS) and MRI/cholangiopancreatography (MRI/MRCP) at each visit.Results366 individuals (201 mutation-negative familial pancreatic cancer (FPC) kindreds and 165 PDAC susceptibility gene mutation carriers; mean age 54 years, SD 9.9) were followed for 63 months on average (SD 43.2). Ten individuals developed PDAC, of which four presented with a symptomatic interval carcinoma and six underwent resection. The cumulative PDAC incidence was 9.3% in the mutation carriers and 0% in the FPC kindreds (p<0.001). Median PDAC survival was 18 months (range 1–32). Surgery was performed in 17 individuals (4.6%), whose pathology revealed 6 PDACs (3 T1N0M0), 7 low-grade precursor lesions, 2 neuroendocrine tumours <2 cm, 1 autoimmune pancreatitis and in 1 individual no abnormality. There was no surgery-related mortality. EUS detected more solid lesions than MRI/MRCP (100% vs 22%, p<0.001), but less cystic lesions (42% vs 83%, p<0.001).ConclusionThe diagnostic yield of PDAC was substantial in established high-risk mutation carriers, but non-existent in the mutation-negative proven FPC kindreds. Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with EUS outperforming MRI/MRCP. Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.

Published
2022
Full Text
View/download PDF

49. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance.

Author

Overbeek, Kasper A., Cahen, Djuna L., Kamps, Anne, Konings, Ingrid C. A. W., Harinck, Femme, Kuenen, Marianne A., Koerkamp, Bas Groot, Besselink, Marc G., van Eijck, Casper H., Wagner, Anja, Ausems, Margreet G. E., van der Vlugt, Manon, Fockens, Paul, Vleggaar, Frank P., Poley, Jan-Werner, van Hooft, Jeanin E., Bleiker, Eveline M. A., Bruno, Marco J., the Dutch Familial Pancreatic Cancer Surveillance Study Group, and Bruno, M. J.

Subjects
PANCREATIC cancer, PATIENTS' attitudes, EXOCRINE pancreatic insufficiency, PANCREATIC surgery, SURGERY
Abstract

In high-risk individuals participating in a pancreatic cancer surveillance program, worrisome features warrant for intensified surveillance or, occasionally, surgery. Our objectives were to determine the patient-reported burden of intensified surveillance and/or surgery, and to assess post-operative quality of life and opinion of surgery. Participants in our pancreatic cancer surveillance program completed questionnaires including the Cancer Worry Scale (CWS) and the Hospital Anxiety and Depression Scale (HADS). For individuals who underwent intensified surveillance, questionnaires before, during, and ≥ 3 weeks after were analyzed. In addition, subjects who underwent intensified surveillance in the past 3 years or underwent surgery at any time, were invited for an interview, that included the Short-Form 12 (SF-12). A total of 31 high-risk individuals were studied. During the intensified surveillance period, median CWS scores were higher (14, IQR 7), as compared to before (12, IQR 9, P = 0.007) and after (11, IQR 7, P = 0.014), but eventually returned back to baseline (P = 0.823). Median HADS scores were low: 5 (IQR 6) for anxiety and 3 (IQR 5) for depression, and they were unaffected by the intensified surveillance period. Of the 10 operated patients, 1 (10%) developed diabetes and 7 (70%) pancreatic exocrine insufficiency. The interviews yielded median quality-of-life scores comparable to the general population. Also, after surgery, patients' attitudes towards surveillance were unchanged (5/10, 50%) or became more positive (4/10, 40%). Although patients were aware of the (sometimes benign) pathological outcome, when asked if surgery had been justified, only 20% (2/10) disagreed, and all would again have chosen to undergo surgery. In conclusion, in individuals at high risk for pancreatic cancer, intensified surveillance temporarily increased cancer worries, without affecting general anxiety or depression. Although pancreatic surgery led to substantial co-morbidity, quality of life was similar to the general population, and surgery did not negatively affect the attitude towards surveillance. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Pancreatic cyst surveillance imposes low psychological burden: preliminary results of the PACYFIC study

Author

Overbeek, Kasper, primary, Kamps, Anne, additional, Van Riet, Priscilla, additional, Di Marco, Mariacristina, additional, Zerboni, Giulia, additional, Van Hooft, Jeanin, additional, Carrara, Silvia, additional, Ricci, Claudio, additional, Gonda, Tamas, additional, Schoon, Erik, additional, Polkowski, Marcin, additional, Beyer, Georg, additional, Honkoop, Pieter, additional, Van der Waaij, Laurens, additional, Casadei, Riccardo, additional, Capurso, Gabriele, additional, Bruno, Marco, additional, Bleiker, Eveline, additional, and Cahen, Djuna, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results